The Experience Matters. Let us show you why. Contact us today.
Pharmacovigilance expert Bart Cobert discusses the FDA and MHRA guidance for non-Corona related clinical trials.
Bart Cobert gives his pharmacovigilance point of view on a recent paper on FDA approval timelines and drug safety issues.
This is an interesting article looking at what PV will be in the year 2030.
Bart Cobert discusses the major safety issue in the US on e-cigarettes and vaping.
Bart Cobert covers several issues involved in setting up the proposed "Safe Importation Plan" which aims to allow US consumers to get safe and cheaper drugs.
An overview covering a number of things to avoid doing when it comes to drug safety.
Bart Cobert explores the potential reasons for the differing regulatory actions from the different agencies.
Bart Cobert discusses the importance of clinical safety reporting. Not only is this a legal responsibility but also an ethical one.
Bart Cobert addresses the use of marijuana for medical purposes and the implications for Drug Safety.
What information should be examined in the study and work up of ADRs to determine whether the reaction is likely due to the drug or not.
Please note: we are currently updating our website which will be live shortly.